Related Experiment Videos
["Multiple sclerosis plus": leukoencephalopathies at the frontiers of internal medicine]
1Service de neurologie, hôpital de la Timone, CHU, 264, rue Saint-Pierre, 13385 Marseille, France. jpelletier@ap-hm.fr
Introduction:
Multiple sclerosis (MS) is an inflammatory, demyelinating and probably autoimmune disease affecting the white matter of the central nervous system (CNS). Due to the absence of specific clinical and laboratory markers, diagnosis remains difficult.
Current Knowledge And Key Points:
In particular, no clinical or paraclinical investigation is satisfactory to distinguish definite MS from other autoimmune or inflammatory diseases, especially when they predominantly affect the CNS. Moreover, previous studies have reported that patients with definite MS could present clinical systemic signs suggestive of other inflammatory or autoimmune diseases, and that MS could be associated with other autoimmune diseases. On the other hand, the presence of biological autoimmune abnormalities, including antinuclear antibodies and antiphospholipid antibodies, has been observed, with a high frequency in patients with MS in comparison to control populations. These clinical and laboratory features could therefore represent a new nosological entity characterized by a systemic immune dysregulation more extensive than the CSN target, or a distinct subgroup of MS patients with a classical course of the disease. Because of the impact of the new therapeutic approach to MS, an important issue concerning this aspect that should be addressed is the use of immunomodulatory therapy, especially with interferon beta. It appears necessary to consider these abnormalities before treating MS patients with preventive therapy, in particular in the perspective of new strategies, such as treatment at an early stage of the disease or combination therapies.
Insights
Multiple sclerosis (MS) diagnosis is challenging due to a lack of specific markers. Systemic autoimmune abnormalities in MS patients may indicate a distinct subgroup or a broader immune dysregulation, impacting treatment decisions.
Area of Science:
- Neurology
- Immunology
- Autoimmune Diseases
Context:
- Multiple sclerosis (MS) is a CNS inflammatory, demyelinating, and autoimmune disease.
- Current diagnostic methods lack specificity, complicating differentiation from other CNS inflammatory conditions.
- MS patients may exhibit systemic autoimmune signs and associated diseases, suggesting broader immune dysregulation.
Purpose:
- To explore the diagnostic challenges in multiple sclerosis (MS).
- To investigate the significance of systemic autoimmune abnormalities in MS patients.
- To assess the implications of these findings for MS treatment strategies, particularly immunomodulatory therapy.
Summary:
- MS diagnosis is difficult due to the absence of specific clinical and laboratory markers.
- High frequency of antinuclear and antiphospholipid antibodies in MS patients suggests systemic immune dysregulation.
- These findings may define a distinct MS subgroup or a new nosological entity.
Impact:
- Highlights the need to consider systemic autoimmunity in MS diagnosis and management.
- Informs decisions regarding immunomodulatory therapies like interferon beta for MS.
- Suggests potential for personalized treatment strategies based on immune profiles in early-stage or combination therapy approaches.